安进

Amgen: Guggenheim Raises PT to $347, Maintains Neutral Rating

Amgen's 15min chart signals Bollinger Bands Narrowing and KDJ Death Cross.

Amgen

Amgen's Earnings Beat Expectations Despite FDA Request to Pull Tavneos from Market

Amgen shares surge 8.4% after-hours on strong Q4 results and raised 2026 guidance despite FDA Tavneos dispute.

Amgen: Citigroup Maintains Neutral, Raises PT to $345 from $315

Catalyst<ul> <li>Fundamental analysis indicates strong cash reserves relative to market value for AMGN.</li></ul>Risk<ul> <li>Technical indicators show that the market is in a weak state, and we need to pay attention to the risk of decline.</li> <li>Bearish signals are obviously dominant with four negative technical indicators reported recently.</li></ul>

Key Factors

Amgen reported Q4 revenue of $9.9 billion, exceeding expectations with 9% YoY growth driven by strong sales of Repatha, Prolia, and TEZSPIRE. The company raised full-year 2026 revenue guidance to $37 billion to $38.4 billion and adjusted EPS guidance to $21.60 to $23.00. Amgen faces regulatory pressure as the FDA requested the withdrawal of Tavneos due to liver health concerns, though the drug accounts for less than 1% of revenue. Enbrel sales declined 48% YoY as biosimilar competition intensified, though overall company revenue still increased by 7%. Multiple analysts, including RBC, Leerink, and Cantor Fitzgerald, raised Amgen’s price targets based on strong Q4 performance and positive pipeline momentum.

AMGN News